Maximizing the Tolerability of Enfortumab Vedotin + Pembrolizumab – The Upcoming New Standard Treatment for Advanced Bladder Cancer

Thomas Powles, Professor of Genitourinary Oncology and Director of Barts Cancer Centre at St. Bartholomew’s Hospital in London, UK, shares in this MEDtalk his insights into managing severe side effects associated with the combination treatment of enfortumab vedotin and pembrolizumab for advanced bladder cancer. He highlights the therapy’s deep and lasting response, underscoring the need to optimize its tolerability as it emerges as the new standard treatment for a broad group of patients with advanced bladder cancer.